#1 Clinical Trials Search in Europe

Bi 764532

BI 764532, also known as Obrixtamig, is an innovative antibody-like molecule being studied in clinical trials for various advanced cancers, including small cell lung cancer, neuroendocrine tumors, and gliomas. This drug is designed to help the immune system fight cancer by targeting a tumor marker called DLL3. The ongoing trials aim to determine the optimal dosage, safety profile, and effectiveness of BI 764532 when used alone or in combination with other treatments.

Table of Contents

What is BI 764532?

BI 764532, also known as Obrixtamig, is a new experimental drug being developed to treat certain types of cancer[1]. It is currently being studied in clinical trials, which means it is not yet approved for general use and is still being tested to determine its safety and effectiveness.

How does BI 764532 work?

BI 764532 is described as an antibody-like molecule that works in a unique way. It is designed to attach to and link together two types of cells in the body[2]:

  1. Cancer cells that have a specific marker called DLL3 (delta-like 3) on their surface
  2. T-cells, which are part of the body’s immune system that helps fight diseases

By connecting these two types of cells, BI 764532 may help the immune system better recognize and attack cancer cells. This approach is known as a DLL3/CD3 bispecific treatment[3].

What conditions does BI 764532 treat?

BI 764532 is being studied for the treatment of several types of cancer, including[4]:

  • Small Cell Lung Cancer (SCLC): A fast-growing type of lung cancer
  • Neuroendocrine Tumors (NETs): Cancers that start in cells of the neuroendocrine system, which is responsible for producing hormones
  • Gliomas: Tumors that occur in the brain and spinal cord

These cancers are specifically targeted because they often have the DLL3 marker on their surface, which BI 764532 is designed to recognize[2].

Current Clinical Trials

Several clinical trials are currently underway to test BI 764532. These trials aim to[4][5][6][7]:

  • Determine the best dose and schedule for the drug
  • Evaluate how well patients tolerate the treatment
  • Assess how effective the drug is at shrinking tumors
  • Study how the drug works in combination with other cancer treatments, such as chemotherapy and immunotherapy

These trials are recruiting patients with advanced cancers who have already tried other treatments without success or for whom no standard treatment exists.

Administration and Dosing

BI 764532 is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein[1]. The frequency of treatment varies depending on the specific trial and dosing schedule being studied. Some trials are testing:

  • Weekly infusions
  • Infusions every 3 weeks
  • Different dose levels to find the optimal amount

Patients in these trials typically continue treatment for as long as they benefit from it and can tolerate the side effects, up to a maximum of 3 years in some studies[3].

Potential Side Effects

As BI 764532 is still in the early stages of testing, the full range of potential side effects is not yet known. The clinical trials are carefully monitoring patients for any adverse events (unwanted effects) that may occur during treatment[4]. Some trials are specifically looking at:

  • Dose-limiting toxicities (DLTs): Side effects that are severe enough to prevent increasing the dose of the drug
  • General health impacts
  • Changes in quality of life

Patients in these trials have regular check-ups and tests to monitor their health and catch any side effects early.

Future Prospects

While BI 764532 shows promise, it’s important to remember that it is still in the experimental stage. The ongoing clinical trials will help determine[4]:

  • How effective the drug is at treating different types of cancer
  • The best way to use BI 764532, either alone or in combination with other treatments
  • The long-term safety profile of the drug

If the results from these trials are positive, BI 764532 could potentially become a new treatment option for patients with small cell lung cancer, neuroendocrine tumors, and other cancers that express the DLL3 marker. However, it will likely be several years before this drug could potentially be approved for widespread use.

Aspect Details
Drug Name BI 764532 (Obrixtamig)
Type DLL3/CD3 bispecific antibody-like molecule
Mechanism Helps immune system target cancer cells expressing DLL3
Cancer Types Studied Small cell lung cancer, neuroendocrine tumors, gliomas
Administration Intravenous infusion
Trial Phases Phase I, Ib, and II
Key Objectives Determine optimal dosage, safety profile, and efficacy
Combination Therapies Tested with chemotherapy and immunotherapy agents
Duration of Treatment Up to 3 years in some trials, based on patient response and tolerance
Monitoring Regular health checks, tumor assessments, and side effect evaluations

FAQ

  • What is BI 764532 and how does it work? BI 764532 (Obrixtamig) is an antibody-like molecule that acts as a DLL3/CD3 bispecific. It can attach to and link together cancer cells and T-cells of the immune system, potentially helping the immune system fight cancer more effectively.
  • What types of cancers are being studied with BI 764532? BI 764532 is being studied in clinical trials for various advanced cancers, including small cell lung cancer, neuroendocrine tumors, and gliomas that are positive for the DLL3 tumor marker.
  • How is BI 764532 administered to patients? BI 764532 is typically administered as an intravenous infusion. The frequency of administration varies depending on the specific trial, ranging from weekly to once every 3 weeks.
  • Are there any side effects associated with BI 764532? As with any experimental treatment, side effects are being closely monitored in the clinical trials. The studies are designed to determine the highest tolerable dose and identify any potential adverse effects. Specific side effect information will be gathered as the trials progress.
  • How long do patients typically receive BI 764532 treatment in these trials? The duration of treatment varies depending on the specific trial and how well patients respond. In some studies, patients may continue treatment for up to 3 years if they benefit from it and can tolerate the medication.

Ongoing Clinical Trials on Bi 764532

  • Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland +2

Glossary

  • DLL3: Delta-like 3, a tumor marker found in certain types of cancers, particularly small cell lung cancer and neuroendocrine tumors.
  • Bispecific antibody: A type of engineered antibody that can bind to two different targets simultaneously, often used to bring immune cells closer to cancer cells.
  • Intravenous infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a dosage reduction.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Neuroendocrine tumor: A type of tumor that forms from cells that release hormones into the blood in response to signals from the nervous system.
  • Glioma: A type of tumor that occurs in the brain and spinal cord, starting in the glial cells that surround and support nerve cells.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Objective response (OR): A measurable response to treatment, typically referring to a reduction in tumor size.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References

  1. https://clinicaltrials.gov/study/NCT05963867
  2. https://clinicaltrials.gov/study/NCT05916313
  3. https://clinicaltrials.gov/study/NCT04429087
  4. https://clinicaltrials.gov/study/NCT05882058
  5. https://clinicaltrials.gov/study/NCT06132113
  6. https://clinicaltrials.gov/study/NCT05990738
  7. https://clinicaltrials.gov/study/NCT06077500